Cwm LLC Lowers Stake in Novo Nordisk A/S (NYSE:NVO)

CWM LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 16.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 78,752 shares of the company's stock after selling 15,842 shares during the quarter. CWM LLC's holdings in Novo Nordisk A/S were worth $5,469,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in NVO. Strategic Investment Solutions Inc. IL raised its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the period. Copeland Capital Management LLC lifted its stake in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. acquired a new position in Novo Nordisk A/S during the 1st quarter worth approximately $27,000. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S in the fourth quarter valued at $29,000. Finally, Transce3nd LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at $33,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NVO. BMO Capital Markets restated a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Finally, Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded down $0.97 during trading hours on Friday, reaching $64.32. The company's stock had a trading volume of 8,032,293 shares, compared to its average volume of 7,376,215. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $139.74. The firm has a 50 day moving average price of $70.34 and a 200-day moving average price of $74.30. The stock has a market cap of $287.19 billion, a P/E ratio of 19.03, a P/E/G ratio of 1.24 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.